Orthocell Ltd has released a press release.
Outstanding Remplir Study Results Pave Way for FDA Clearance
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Orthocell
- Distributor Signed, Remplir Sales in Singapore to Commence
- Key Executives Appointed to Drive Remplir US Sales
- Orthocell completes $17m Placement
- $17m Placement to Drive Further Growth as US Approval Nears
- Regulatory approval to commence Remplir sales in Singapore
Later from Orthocell
- Major Milestone with First Sales of Remplir in Singapore
- US FDA Application Submitted for Remplir as US Launch Nears
- Third Consecutive Quarter of Record Revenue for Orthocell
- Orthocell Receives $3.18 million R&D Tax Refund
- S&P DJI Announces March 2025 Quarterly Rebalance
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell